/SNDL
SNDL Stock - SNDL Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.92-5.88%
$0.12 (-5.88%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+145.3%upside
Target: $4.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNDL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.90 – $1.94
TARGET (TP)$4.71
STOP LOSS$1.77
RISK/REWARD1:18.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.58
52W High$2.89
52W Low$1.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $920.45M | $909.01M | $712.20M | $56.13M | $60.92M |
| Gross Profit | $240.33M | $190.41M | $140.38M | $-9,001,000 | $-49,869,000 |
| Gross Margin | 26.1% | 20.9% | 19.7% | -16.0% | -81.9% |
| Operating Income | $-103,811,000 | $-163,171,000 | $-347,774,000 | $-134,376,000 | $-185,404,000 |
| Net Income | $-94,796,000 | $-172,660,000 | $-335,114,000 | $-226,984,000 | $-233,246,000 |
| Net Margin | -10.3% | -19.0% | -47.1% | -404.4% | -382.9% |
| EPS | $-0.38 | $-0.65 | $-1.50 | $-1.24 | $-9.50 |
Company Overview
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$4
Average Target
↑ 85.8% Upside
Now
$1
Low
$4
Average
$5
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 3rd 2025 | Alliance Global Partners | Initiation | Buy | $5 |
| July 17th 2024 | Canaccord Genuity | Resumed | Speculative Buy | - |
| August 16th 2022 | Canaccord Genuity | Upgrade | Speculative Buy | $5 |
| May 3rd 2022 | BMO Capital Markets | Upgrade | Market Perform | $0.7← $0.6 |
Earnings History & Surprises
SNDLBeat Rate
27%
Last 15 quarters
Avg Surprise
-1262.8%
EPS vs Estimate
Beats / Misses
4/11
Last 12 quarters
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
-83.3%
$-0.22vs$-0.12
Q2 24
+75.0%
$-0.01vs$-0.04
Q3 24
+75.0%
$-0.01vs$-0.04
Q4 24
-40.0%
$-0.05vs$-0.04
Q1 25
-1800.0%
$-0.19vs$-0.01
Q2 25
+33.3%
$-0.04vs$-0.06
Q3 25
+125.0%
$0.01vs$-0.04
Q4 25
-11011.1%
$-0.04vs$-0.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $0.01 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.00 | $-0.04 | -11011.1% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-0.04 | $0.01 | +125.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.01 | $-0.19 | -1800.0% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-0.04 | $-0.05 | -40.0% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q1 2024 | Mar 20, 2024 | $-0.12 | $-0.22 | -83.3% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $0.01 | $-0.06 | -915.2% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $0.01 | $-0.08 | -1161.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $0.01 | $-0.07 | -1047.2% | ✗ MISS |
Q2 2023 | Apr 24, 2023 | $0.01 | $-0.13 | -981.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.00 | $-0.02 | -925.6% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.01 | $-0.08 | -985.5% | ✗ MISS |
Q2 2022 | May 16, 2022 | — | $-0.20 | — | — |
Q2 2022 | Apr 27, 2022 | $-0.05 | $-0.20 | -300.0% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | — | $0.10 | — | — |
Q3 2021 | Aug 12, 2021 | — | $0.10 | — | — |
Latest News
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher after US House Representative Mast joined the Marijuana 1-to-3 Act of 2025 as its newest cosponsor.
📈 PositiveBenzinga•Nov 24, 2025, 05:02 PM•Also: , ,
'GOP Representative Brian Mast Signs On As Sponsor Of Bipartisan Legislation To Reschedule Cannabis' - Marijuana Herald
📈 PositiveBenzinga•Nov 24, 2025, 04:19 PM•Also: , ,
SNDL Wins CSE Approval For Share Repurchase Program, Authorizing Up To C$100M; May Only Repurchase A Maximum Of ~24.5M Shares Under The Share Repurchase Program, Representing 10% Of The Public Float Of The Company
📈 PositiveBenzinga•Nov 21, 2025, 09:38 PM
NBC News Congressional Correspondent Julie Tsirkin Posts On X "POTUS "supports the current language in the bill on hemp," per WH official. Sen Rand Paul has long told leadership + industry folks he won't consent to bills unless the loophole is preserved, created by the 2018 farm bill that allows unregulated THC products to be sold nationwide"
➖ NeutralBenzinga•Nov 10, 2025, 06:57 PM•Also: , ,
SNDL shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 02:02 PM
SNDL Q3 EPS $(0.05) Misses $(0.02) Estimate, Sales $244.219M Beat $242.976M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 11:57 AM
'MAGA And Marijuana Might Become Best Buds; The President Is Open To Loosening Federal Cannabis Rules. 'It's Good Politics,' A White House Official Says; President Donald Trump Is Weighing Reclassification Of Cannabis From A Schedule I Drug To Schedule III' - The Free Press
📈 PositiveBenzinga•Oct 16, 2025, 02:32 PM•Also: , ,
Frequently Asked Questions about SNDL
What is SNDL's current stock price?
SNDL Inc. (SNDL) is currently trading at $1.92 per share. The stock has moved -5.88% today.
What is the analyst price target for SNDL?
The average analyst price target for SNDL is $4.71, based on 1 analyst.
What sector is SNDL Inc. in?
SNDL Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is SNDL's market cap?
SNDL Inc. has a market capitalization of $0.49 billion, making it a small-cap company.
Does SNDL pay dividends?
No, SNDL Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKBA
Akebia Therapeutics, Inc.
$1.66
Mkt Cap: $0.4B
AQST
Aquestive Therapeutics, Inc.
$5.80
Mkt Cap: $0.6B
CMPS
COMPASS Pathways plc
$6.37
Mkt Cap: $0.6B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
EBS
Emergent BioSolutions Inc.
$12.42
Mkt Cap: $0.7B
EOLS
Evolus, Inc.
$7.07
Mkt Cap: $0.5B
ESPR
Esperion Therapeutics, Inc.
$3.93
Mkt Cap: $0.8B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
ORGO
Organogenesis Holdings Inc.
$5.60
Mkt Cap: $0.7B
SIGA
SIGA Technologies, Inc.
$6.27
Mkt Cap: $0.4B
Explore stocks similar to SNDL for comparison